# OnCo record adela (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/adela/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "adela" ;
  schema:name "Adela"@en ;
  schema:description "Adela, of Toronto, develops blood tests that profile methylation marks across all cell-free DNA fragments without sequencing the tumour itself, first to detect residual disease and immunotherapy response in advanced solid tumours and later to screen for multiple cancers with one test. The screening programme is still in study."@en ;
  schema:url <https://onco.cc/companies/adela/>, <https://www.adelabio.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.adelabio.com/>, <https://www.adelabio.com/press/adela-debuts-with-60m>, <https://www.adelabio.com/press/adela-announces-48-million-in-financing-and-leadership-addition-to-advance-tissue-agnostic-minimal-residual-disease-mrd-monitoring-product-portfolio-based-on-genome-wide-methylome-approach>, <https://www.adelabio.com/adela-news> ;
  schema:addressCountry "CA" ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/early-detection/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/mced/> .